| CONTENTS |
| No Longer a Hit-or-Miss Proposition: Once-Daily Formulation for Drugs with pH-Dependent Solubility Gopi Venkatesh, Director of R&D Anthony Recupero, Senior Director, Business Development Aptalis Pharmaceutical Technologies |
| A possible approach for the desire to innovate Brian Wang, CEO & Dr Junsang Park, CSO GL PharmTech |
| Company Profile Mayne Pharma International |
| From Powder to Pill: A Rational Approach to Formulating for First-into-Man Studies Dr Robert Harris, Director, Early Development Molecular Profiles Ltd |
| LiquiTime Oral Liquid Controlled Release Drug Delivery Platform Camille Rivail, Business Development Analyst Dr Jean Chatellier, Vice-President, Alliance Management Flamel Technologies SA |
| Formulation Flexibility Broadens the Scope for Oral Thin Film Technology Martha Sloboda, Business Manager Dr Scott Barnhart, Technical Director ARx LLC |
| Solumer™ Technology: a Viable Oral Dosage Form Option for BCS Class II Molecules Dr Robert Lee, VP, Pharmaceutical Development, Particle Sciences Inc & Dr Amir Zalcenstein, CEO, Solubest Ltd Particle Sciences Inc & Solubest Ltd |
| Controlled Drug Release: Novel Time-Delayed Formulations and their Clinical Evaluation Dr Carol Thomson, COO Drug Delivery International Ltd |
| Liquid-Fill Hard Two-Piece Capsules: The Answer to Many Product Development Issues Mr Gary Norman, Product Development Manager Encap Drug Delivery |
| Multi-Tip Tooling: A Guide Dale Natoli, Vice-President Natoli Engineering Company, Inc |